Eli Lilly and Company and AstraZeneca entered into an agreement Friday to co-develop a moment new drug candidate targeting Alzheimer's disease.
Under the terms of the deal,Lilly (NYSE: LLY) will gain an upfront payment of $30 million to AstraZeneca (NYSE: AZN).
The agreement, the companies said, or builds on their existing collaboration related to another potential Alzheimer's drug,called AZD3293, that is in late stage clinical testing.
Their moment new drug candidate, or MEDI1814,is in early clinical…
Source: bizjournals.com